Most treatment strategies currently being pursued have arisen from the genetic, biochemical, and morphologic data implicating the amyloid precursor protein (APP) and the amyloid-β peptide (Aβ) products from proteolytic processing in the pathogenesis of AD (Toyn et al., 2014). Here, APP is linked to Alzheimer disease.